Ensysce Biosciences (ENSC) Projected to Post Quarterly Earnings on Wednesday

Ensysce Biosciences (NASDAQ:ENSC) is projected to release its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $0.67 million for the quarter.

Ensysce Biosciences (NASDAQ:ENSC) last issued its earnings results on Tuesday, May 13th. The company reported ($1.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.02) by $1.63. The firm had revenue of $1.32 million during the quarter, compared to analyst estimates of $0.65 million. Ensysce Biosciences had a negative net margin of 109.49% and a negative return on equity of 192.54%. On average, analysts expect Ensysce Biosciences to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Ensysce Biosciences Stock Performance

NASDAQ:ENSC opened at $2.08 on Tuesday. The business’s fifty day moving average is $2.18 and its 200 day moving average is $3.17. Ensysce Biosciences has a 52-week low of $1.62 and a 52-week high of $14.67. The firm has a market cap of $4.93 million, a price-to-earnings ratio of -0.32 and a beta of 1.00.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Ensysce Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.